Merck
Beyond's analysis on Merck
- — Merck KGaA expands life science footprint through shareholder-approved acquisition of Bio-Techne
- — Amgen vs. Merck: Comparing dividend growth prospects for income investors
- — Approval of Merck's oral PCSK9 inhibitor LIPFENDRA and emerging oral competitors signal a high‑growth phase for the PCSK9 inhibitor market
- — Merck raises full-year guidance after Q2 beat driven by AI and oncology strength
- — Patent expirations on blockbuster drugs threaten $440 billion in pharma revenues, with Merck-MSD and AbbVie most exposed
Recent news mentioning Merck
- — Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
- — Merck Manuals Details What Patients Need to Know About Inflammatory Bowel Disease
- — Could You Have Seen Merck Stock's Pipeline Run Coming?
- — Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
- — Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
- — Merck Stock Nearly Doubled Without A Change In Its Revenue Growth
- — Merck & Co. (MRK) is Building a Stronger Future Beyond Its Keytruda Franchise
- — Merck Stock: Is The $70 Billion Pipeline Worth the Premium?
- — Eli Lilly Vs. Merck: One is a No-Brainer to Hold Through 2030
- — Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
- — Jim Cramer Explains Why Merck (MRK) Is His Fantasy Defense Stock
- — Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat